Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder
03.10.2022 - TNX-601 ER, Tianeptine Hemioxalate, is an Extended-Release Tablet for Once-a-Day Dosing Phase 2 Clinical Trial of TNX-601 ER Expected to Start First Quarter 2023 CHATHAM, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) - Tonix Pharmaceuticals Holding ... Seite 1
United States Tianeptine Hemioxalate Seth Lederman Tonix Pharmaceuticals Tonix Pharmaceuticals Holding Corp Drug Administration
Source: wallstreet-online.de